Licensing of pharmaceutical representatives (SB 763) RAC

The Department of Consumer and Business Services (DCBS) is preparing to begin rulemaking on the licensing of pharmaceutical representatives specifically for SB 763 enacted during the 2021 Legislative Session. This bill provides that a person may not engage in business as pharmaceutical representative without obtaining a license from the director of DCBS.

Temporary Rules for Pharmaceutical Sales Representative Licensing.

All meetings held via Microsoft Teams meetings.
Join on your computer or mobile app.*
*Download the Microsoft Teams app

Committee Contacts:

Numi Lee Griffith
Senior Policy Adviser
Division of Financial Regulation
Numi.L.Griffith@dcbs.oregon.gov
Phone: 503-428-4723

Karen Winkel
Rules Coordinator
Division of Financial Regulation
Karen.J.Winkel@dcbs.oregon.gov
Phone: 503-947-7694

On May 26, 2022 a rulemaking hearing was held regarding proposed adoption of Pharmaceutical Representative Licensing Rules pursuant to SB 763.

Public comments solicited at this hearing and submitted within the deadline are included here for the public record.

5/27/2022
Judy Fox
QPharma

5/27/2022
Maribeth Guarino
OSPIRG

5/27/2022
Chelsea Ott
MedPro Systems

5/27/2022
Brian Van Hoy
G&M Health

5/26/2022
Nikki Reeves, Seth Lundy, Brian Bohnenkamp, Caitlyn Ozier
King & Spalding LLP on behalf of Ad Hoc Sunshine and State Law Compliance Group

5/26/2022
Chloe Becker
OCAP

5/25/2022
Deanne Calvert
Sanofi

3/17/2022
Dharia McGrew, Sandy Ahn
PhRMA

Anne Murray
Bristol-Myers-Squibb

Asher Lisec
PhRMA

Brian Van Hoy
G&M Health, LLC

Chloe Becker
OCAP

Jen Baker
Providence

Maribeth Guarino
OSPIRG

Mark Bonanno
Oregon Medical Association

Rick Blackwell
PacificSource